摘要
Metabolic associated fatty liver disease(MAFLD),previously termed nonalcoholic fatty liver disease,is the leading global cause of liver disease and is fast becoming the most common indication for liver transplantation.The recent change in nomenclature to MAFLD refocuses the conceptualisation of this disease entity to its metabolic underpinnings and may help to spur a paradigm shift in the approach to its management,including in the setting of liver transplantation.Patients with MAFLD present significant challenges in the pre-,peri-and posttransplant settings,largely due to the presence of medical comorbidities that include obesity,metabolic syndrome and cardiovascular risk factors.As the community prevalence of MAFLD increases concurrently with the obesity epidemic,donor liver steatosis is also a current and future concern.This review outlines current epidemiology,nomenclature,management issues and outcomes of liver transplantation in patients with MAFLD.
作者简介
Corresponding author:Avik Majumdar,MBBS,MPHTM,FRACP,PhD,Senior Lecturer,Staff Physician,AW Morrow Gastroenterology and Liver Centre,Royal Prince Alfred Hospital,Sydney 2050,New South Wales,Australia.avik.majumdar@health.nsw.gov.au.ORCID number:Madeleine G Gill 0000-0002-4201-0173;Avik Majumdar 0000-0003-2975-4327.
